B Cell Lymphoma
Expert Perspective
The Evolving Treatment Paradigm for Diffuse Large B-Cell Lymphoma
Conference Coverage
Relapsed DLBCL: With Complete Interim Response, SCT Outperforms CAR T
Awaiting CAR T therapy, patients with complete response to interim chemo show better outcomes with subsequent autologous transplantation, compared...
News
FDA approves pirtobrutinib for previously treated CLL/SLL
FDA greenlights pirtobrutinib as third-line treatment for chronic lymphocytic leukemia or small lymphocytic lymphoma in adults.
News
‘Promising’ new txs for most common adult leukemia
The FDA has already approved these treatments for some other blood cancers, but chronic lymphocytic leukemia (CLL) poses unique challenges.
News
Lymphoma specialist to lead MD Anderson’s cancer medicine division
Dr. Christopher Flowers, a prominent African American oncologist with expertise in blood cancer and health disparity research, heads a key...
News
CLL combo treatment: Phase-3 study inconclusive
Results of the clinical trial of a CLL drug triplet therapy, presented at ASCO 2023, showed that more data are needed to determine its long-term...
Conference Coverage
CLL: Venetoclax-obinutuzumab combo effective long term
Progression-free survival benefit of 1 year with venetoclax-obinutuzumab is sustained long term in chronic lymphocytic leukemia, trial analysis...
Conference Coverage
`Remarkable’: CAR T therapy for CLL/SLL
Primary analysis of the TRANSCEND CLL 004 trial showed that a single dose of CAR T therapy achieved durable responses in CLL and SLL, with a...
Conference Coverage
PMBCL: Postremission, patients may safely skip radiation
Among patients who had achieved complete remission of primary mediastinal B-cell lymphoma with chemotherapy, the largest study of its kind found...
News
DLBCL: Major new treatment breakthroughs
After decades of slow progress, new drugs and therapies are paving the way to more effective treatment of DLBCL.